Cargando…
A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups
BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreove...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370855/ https://www.ncbi.nlm.nih.gov/pubmed/34422649 http://dx.doi.org/10.3389/fonc.2021.696147 |
_version_ | 1783739519692963840 |
---|---|
author | Gao, Yuting Wei, Li Kim, Seok Jin Wang, Liang He, Yingzhi Zheng, Yanfang Bertero, Luca Pellerino, Alessia Cassoni, Paola Tamagnone, Luca Theresa, Prochazka Katharina Deutsch, Alexander Zhan, Huien Lai, Jing Wang, Yao You, Hua |
author_facet | Gao, Yuting Wei, Li Kim, Seok Jin Wang, Liang He, Yingzhi Zheng, Yanfang Bertero, Luca Pellerino, Alessia Cassoni, Paola Tamagnone, Luca Theresa, Prochazka Katharina Deutsch, Alexander Zhan, Huien Lai, Jing Wang, Yao You, Hua |
author_sort | Gao, Yuting |
collection | PubMed |
description | BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. METHODS: We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. RESULTS: By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. CONCLUSIONS: In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. |
format | Online Article Text |
id | pubmed-8370855 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-83708552021-08-19 A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups Gao, Yuting Wei, Li Kim, Seok Jin Wang, Liang He, Yingzhi Zheng, Yanfang Bertero, Luca Pellerino, Alessia Cassoni, Paola Tamagnone, Luca Theresa, Prochazka Katharina Deutsch, Alexander Zhan, Huien Lai, Jing Wang, Yao You, Hua Front Oncol Oncology BACKGROUND: Primary central nervous system lymphoma (PCNSL) is a highly aggressive and rare extranodal non-Hodgkin lymphoma (NHL). The MSKCC and the IELSG scores represent the most widely used prognostic models, but many changes have occurred in therapeutic protocols since their development. Moreover, many PCNSL patients cannot be classified using the IELSG score. We thus aimed to create a novel, effective and feasible prognostic model for PCNSL. METHODS: We included 248 PCNSL patients diagnosed with PCNSL. Our primary endpoint was the overall survival (OS) and we used the receiver operating characteristic (ROC) analysis to determine the optimal prognostic cut-off value for LLR (lactate dehydrogenase-to-lymphocyte ratio), neutrophil-to-lymphocyte ratio (NLR) and derived neutrophil-to-lymphocyte ratio (dNLR). Variable associated with OS were evaluated by univariate and multivariate analyses. 124 out of 248 patients were randomly selected as the internal validation cohort. RESULTS: By univariate analysis, an age >60 years, Eastern Cooperative Oncology Group performance status (ECOG PS) >1, treatment with radiotherapy alone, high-risk groups of Memorial Sloan Kettering Cancer Center (MSKCC) score, NLR >4.74, dNLR >3.29, and LLR >166.8 were significantly associated with a worse OS. By multivariate analysis, the MSKCC score and LLR were confirmed as independent prognostic parameters for poorer OS. OS, however, was not significantly different between low- and intermediate-risk groups according to the MSKCC score, while LLR proved to be prognostically relevant and was thus used to develop a novel, effective three-tier PCNSL scoring system. Of 124 patients, 84 patients with survival data and LLR data were successfully validated by newly established PCNSL LLR scoring system. CONCLUSIONS: In the present study, we demonstrate that a high LLR represents an independent unfavorable prognostic parameter in PCNSL patients which can be integrated into an effective prognostic model. Frontiers Media S.A. 2021-08-03 /pmc/articles/PMC8370855/ /pubmed/34422649 http://dx.doi.org/10.3389/fonc.2021.696147 Text en Copyright © 2021 Gao, Wei, Kim, Wang, He, Zheng, Bertero, Pellerino, Cassoni, Tamagnone, Theresa, Deutsch, Zhan, Lai, Wang and You https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Gao, Yuting Wei, Li Kim, Seok Jin Wang, Liang He, Yingzhi Zheng, Yanfang Bertero, Luca Pellerino, Alessia Cassoni, Paola Tamagnone, Luca Theresa, Prochazka Katharina Deutsch, Alexander Zhan, Huien Lai, Jing Wang, Yao You, Hua A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title | A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_full | A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_fullStr | A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_full_unstemmed | A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_short | A Novel Prognostic Marker for Primary CNS Lymphoma: Lactate Dehydrogenase-to-Lymphocyte Ratio Improves Stratification of Patients Within the Low and Intermediate MSKCC Risk Groups |
title_sort | novel prognostic marker for primary cns lymphoma: lactate dehydrogenase-to-lymphocyte ratio improves stratification of patients within the low and intermediate mskcc risk groups |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370855/ https://www.ncbi.nlm.nih.gov/pubmed/34422649 http://dx.doi.org/10.3389/fonc.2021.696147 |
work_keys_str_mv | AT gaoyuting anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT weili anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT kimseokjin anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT wangliang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT heyingzhi anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT zhengyanfang anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT berteroluca anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT pellerinoalessia anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT cassonipaola anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT tamagnoneluca anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT theresaprochazkakatharina anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT deutschalexander anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT zhanhuien anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT laijing anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT wangyao anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT youhua anovelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT gaoyuting novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT weili novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT kimseokjin novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT wangliang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT heyingzhi novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT zhengyanfang novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT berteroluca novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT pellerinoalessia novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT cassonipaola novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT tamagnoneluca novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT theresaprochazkakatharina novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT deutschalexander novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT zhanhuien novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT laijing novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT wangyao novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups AT youhua novelprognosticmarkerforprimarycnslymphomalactatedehydrogenasetolymphocyteratioimprovesstratificationofpatientswithinthelowandintermediatemskccriskgroups |